Telix and Regeneron to co-develop radiopharmaceutical therapies

Telix and Regeneron Pharmaceuticals person entered a concern for the improvement and commercialisation of caller radiopharmaceutical therapies.

This collaboration aims to integrate Telix's expertise successful radiopharmaceutical platforms, planetary manufacturing and proviso concatenation infrastructure with Regeneron's biologics knowledge, peculiarly successful bispecific antibody discovery.

Regeneron volition initially supply Telix with an upfront currency outgo of $40m for entree to the latter’s radiopharmaceutical manufacturing level for 4 therapeutic initiatives.

There is an enactment for Regeneron to grow to different 4 programmes, which would impact further upfront payments. Both companies volition arsenic stock the costs and imaginable profits worldwide, with Telix optionally co-promoting definite products.

If Telix chooses to measurement backmost from backing a circumstantial programme, it could summation up to $535m successful developmental and commercialized milestones, successful summation to debased double-digit royalties connected consequent nett sales.

Regeneron oncology and antibody exertion probe elder vice-president John Lin said: “At Regeneron, we travel the subject to find the champion therapeutic attack for each disease, continuously expanding our toolbox of attraction modalities – from monoclonal and bispecific antibodies to compartment therapies and beyond.

“Targeted radiopharmaceuticals correspond a rapidly emerging frontier successful oncology and an breathtaking accidental to bring caller attraction options to patients successful need.”

The collaboration volition see respective coagulated tumour targets from Regeneron's antibody portfolio, benefiting from its VelocImmune mice technology.

It reflects a associated absorption connected precision oncology, seeking to heighten diligent enactment and measure attraction responses done caller radio-diagnostics.

The companies besides program to make diagnostic assets, wherever Telix volition spearhead the commercialisation efforts, and Regeneron volition person a predetermined stock of the profits.

In December 2025, Regeneron teamed up with Tessera Therapeutics to make and commercialise Tessera’s uncommon illness successful vivo cistron penning programme, TSRA-196.

"Telix and Regeneron to co-develop radiopharmaceutical therapies" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.